OS Therapies Inc (OSTX) stock
OSTXNYSEPharmaceutical PreparationsFiscal year ends December 31
$0.74+0.06 (+9.42%)
Close on Nov 17, 2026Market cap $34.35MP/E –Yield –
OS Therapies operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
OS Therapies's operating income for the twelve months ending Jun 30, 2026 was -$37.61M. For fiscal 2025 it was -$28.71M.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$28.71M | – |
| FY2024 | Dec 31, 2024 | -$6.81M | – |
| FY2023 | Dec 31, 2023 | -$4.34M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$8.58M | – |
| Q1 FY2026 | Mar 31, 2026 | -$10.17M | – |
| Q4 FY2025 | Dec 31, 2025 | -$11.99M | – |
| Q3 FY2025 | Sep 30, 2025 | -$6.88M | – |
| Q2 FY2025 | Jun 30, 2025 | -$4.84M | – |
| Q1 FY2025 | Mar 31, 2025 | -$5.00M | – |
| Q4 FY2024 | Dec 31, 2024 | -$2.97M | – |
| Q3 FY2024 | Sep 30, 2024 | -$2.44M | – |
| Q2 FY2024 | Jun 30, 2024 | -$779.80K | – |
| Q1 FY2024 | Mar 31, 2024 | -$630.23K | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.16M | – |
| Q3 FY2023 | Sep 30, 2023 | -$622.21K | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.52M | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.05M | – |
See a number that looks wrong?